Skip to main content
SpringerLink
Log in

A Phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer

  • Originals
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Recombinant human tumor necrosis factor (TNF) is a cytotoxic monokine with immunomodulatory functions. Gamma interferon (g-IFN) synergizes with TNF in many ways. We therefore conducted a Phase I/II combination trial with TNF and g-IFN at an immunomodulatory dose level in 16 patients with colorectal cancer. TNF (50 μg/m2 in a 30 min infusion) and g-IFN (100 μg in subcutaneous injections) were administered daily Monday through Friday for 4 weeks. Two cases of major toxicity, one acute renal failure and one case of severe thrombocytopenia, led to discontinuation of study medication in these patients. Toxicities in remaining patients were manageable with conservative treatment. Changes in laboratory values included leukopenia, anemia and thrombocytopenia. Alterations in lipid metabolism and changes in serum levels of acute phase proteins were observed. Increase in both total lymphocytes and a Leu 11 positive subpopulation, as well as an induction of measurable interleukin 2 serum levels in a subgroup of patients, were noted. Response results of 14 evaluable patients were one patient with a mixed response, 4 with stable disease and 9 with disease progression. Median survival was 23.5 weeks with only one patient alive after 71 weeks. Therefore the drug combination of TNF/g-IFN in the chosen regimen cannot be recommended for the treatment of patients with colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

TNF:

tumor necrosis factor

g-IFN:

gamma-interferon

TGF:

transforming growth factor

GM-CSF:

granulocyte-macrophage colony-stimulating factor

IL-1:

interleukin-1

IL-2:

interleukin-2

MHC:

Major histocompatibility complex

MTD:

maximally tolerated dose

Ig:

immunoglobulin

References

  1. Abbruzzese JL, Levin B, Ajani JF, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU (1989) Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res 49:4057–4061

    Google Scholar 

  2. Aggarwal BB, Eessalu TE, Hass PE (1985) Characterisation of receptors for human tumor necrosis factor and their regulation by g-interferon. Nature 318:665–667

    Google Scholar 

  3. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W (1986) Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 46:3990–3993

    Google Scholar 

  4. Beissert S, Bergholz M, Waase I, Lepsien G, Schauer A, Pfizenmaier K, Krönke M (1989) Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci USA 86:5064–5068

    Google Scholar 

  5. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 319:516–518

    Google Scholar 

  6. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YCE, Mathison J, Ulevitch R, Cerami A (1985) Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552–554

    Google Scholar 

  7. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 83:4533–4537

    Google Scholar 

  8. Collart MA, Belin D, Vassalli J-D, DeKossodo S, Vassalli P (1986) Gamma interferon enhances macrophage transscription of the tumor necrosis factor/cachectin interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J exp Med 164:2113–2118

    Google Scholar 

  9. Creasey AA, Reynolds MT, Laird W (1986) Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 46:5687–5690

    Google Scholar 

  10. Demetri GD, Spriggs DR, Sherman ML, Arthur KA, Imamura K, Kufe DW (1989) A phase I trial of recombinant tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo. J Clin Oncol 7:1545–1553

    Google Scholar 

  11. Ernstoff MS, Reich S, Nishoda Y, Kirkwood JM (1985) Immunological assessment of melanoma patients treated with recombinant interferon gamma in a phase I/II trial. Immunology 26:280–286

    Google Scholar 

  12. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard M, Palladino MA (1987) Inhibition of cytokine production by cyclosporin A and transforming growth factorβ. J exp Med 166:571–576

    Google Scholar 

  13. Feinman R, Henriksen-DeStefano D, Tsujimoto M, Vilcek J (1987) Tumor necrosis factor is an important mediator of killing by human monocytes. J Immunol 138:635–640

    Google Scholar 

  14. Fraker DL, Stovroff MC, Merino MJ, Norton JA (1988) Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J exp Med 168:95–105

    Google Scholar 

  15. Gamble JR, Harlan JM, Klobanoff SJ, Vadas MA (1985) Stimulation of the adherence of neutrophiles to umbilical vein endothelium by recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82:8667–8671

    Google Scholar 

  16. Grunfeld C, Wilking H, Neese R, Gavin LA, Moser AH, Gulli R, Serio MK, Feingold KR (1989) Persistance of the hypertriglyceridemic effect of tumor necrosis factor despite development of tachyphylaxis to its anorectic/cachectic effects in rats. Cancer Res 49:2554–2560

    Google Scholar 

  17. Haranka K, Satomi N, Sakurai A (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34:263–267

    Google Scholar 

  18. Havell EA, Fiers W, North RJ (1988) The antitumor function of tumor necrosis factor (TNF): therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J exp Med 167:1067–1085

    Google Scholar 

  19. Heidenreich S, Weyers M, Gong JH, Sprenger H, Nain M, Gemsa D (1988) Potentiation of lymphokine-induced marcrophage activation by tumor necrosis factor-alpha. J Immunol 140:1511–1518

    Google Scholar 

  20. Holm G, Sture N (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6:65–70

    Google Scholar 

  21. Jakubowski AA, Casper ES, Gabrilove JL, Templeton MA, Sherwin SA, Oettgen HF (1989) Phase I trial of intramuscularily administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 7:298–303

    Google Scholar 

  22. Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD (1989) Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74:130–138

    Google Scholar 

  23. Kaushansky K, Broudy VC, Harlan JM, Adamson JW (1988) Tumor necrosis factor-alpha and tumor necrosis factor-beta (lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IL-1 in vivo. J Immunol 141:3410–3415

    Google Scholar 

  24. Kehrl JH, Miller A, Fauci AS (1987) Effect of tumor necrosis factor on mitogen-activated human B cells. J exp Med 166:786–791

    Google Scholar 

  25. Kettelhut IC, Fiers W, Goldberg AL (1987) The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci USA 84:4273–4277

    Google Scholar 

  26. Kunkel SL, Wiggins RC, Chensue SW, Larrick J (1986) Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Comm 137:404–410

    Google Scholar 

  27. Logan TF, Virji MA, Kirkwood JM, Ernstoff MS, Whiteside TL, Bontempo FA, Prescott K, Wood D, Nadler P (1989) Tumor necrosis factor (TNF) effects on NK activity, LAK generation, PMN-induced growth inhibition vs Daudi, tissue plasminogen activator/inhibitor and granulocyte kinetics observed in a phase I trial. Proc Annu Meet Am Soc Clin Oncol 8:A758 (abstract)

    Google Scholar 

  28. Nawroth P, Handley D, Matsueda G, DeWaal R, Gerlach H, Blohm D, Stern D (1988) Tumor necrosis factor/cachectin-induced intravascular fibrin formation in Meth A fibrosarcomas. J exp Med 168:637–647

    Google Scholar 

  29. North RJ, Havell EA (1988) The antitumor function of tumor necrosis factor (TNF): analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J exp Med 167:1086–1099

    Google Scholar 

  30. Old LJ (1985) Tumor necrosis factor (TNF). Science 230:630–632

    Google Scholar 

  31. Palladino jr MA, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS, Liggit D, Patton JS (1987) Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 138:4023–4027

    Google Scholar 

  32. Pessara U, Momburg F, Koch N (1988) Cooperative effect of interferon-gamma and tumor necrosis factor-alpha on the induction of the class II antigen-associated invariant chain expression. Eur J Immunol 18:1719–1726

    Google Scholar 

  33. Philip R, Epstein LB (1986) Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 323:86–89

    Google Scholar 

  34. Porber JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA (1986) Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 136:1680–1687

    Google Scholar 

  35. Robertson PA, Ross HJ, Figlin RA (1989) Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma. Annal Int Med 111:682–684

    Google Scholar 

  36. Sato N, Fukuda K, Nariuchi H, Sagara N (1987) Tumor necrosis factor inhibiting angiogenesis in vitro. JNCI 79:1383–1388

    Google Scholar 

  37. Scheurich P, Thoma B, Ücer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138:1786–1790

    Google Scholar 

  38. Scuderi P, Dorr RT, Liddil JD, Finley PR, Meltzer P, Raitano AB, Rybski J (1989) Alpha-globulins suppress human leukocyte tumor necrosis factor secretion. Eur J Immunol 19:939–942

    Google Scholar 

  39. Seckinger P, Isaaz S, Dayer JM (1988) A human inhibitor of tumor necrosis factor alpha. J exp Med 167:1511–1516

    Google Scholar 

  40. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA (1985) Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol 135:2069–2073

    Google Scholar 

  41. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD, Shires GT, Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474

    Google Scholar 

  42. Waterhouse J, Muir C, Correa P, Powell J (1976) Cancer incidence in five continents. Vol 3, International Agency for Reseach on Cancer, Lyon

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Onkologie/Hämatologie der Medizinischen Klinik und Institut für Biomathematik und Informatik der Universitätsklinik Eppendorf, Hamburg

    W. Fiedler, W. Zeller, C. -J. Peimann, H. -J. Weh & D. K. Hossfeld

Authors
  1. W. Fiedler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Zeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. -J. Peimann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. -J. Weh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. K. Hossfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Unterstützt von der Deutschen Forschungsgemeinschaft (W.F.) und Boehringer, Ingelheim

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fiedler, W., Zeller, W., Peimann, C.J. et al. A Phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer. Klin Wochenschr 69, 261–268 (1991). https://doi.org/10.1007/BF01666852

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01666852

Key words

Search

Navigation